Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 11;31(3):455–470. doi: 10.1093/hmg/ddab256

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Differences in systemic complement levels and complement GRS in AMD patients and control individuals. (A) FH, (B) C3bBbP levels in plasma and (C) the complement GRS are shown for non-carriers and CFH rare variant carriers stratified by phenotype (no AMD, early/intermediate AMD and advanced AMD). (A–C) Mean and SD are shown by error bars, and (A, B) mean ± 2 SD is indicated by dotted lines. (C) Dotted lines indicate the tertiles of the complement GRS based on a large AMD case–control cohort (de Breuk et al., submitted for publication). Carriers and non-carriers within each AMD stage were compared with one-way ANOVA and Sidak’s multiple comparison test, and significant P-values are indicated with ^*<0.05, ^*^*<0.01, ^*^*^*<0.001 and ^*^*^*^*<0.0001.